{
    "clinical_study": {
        "@rank": "62288", 
        "brief_summary": {
            "textblock": "To determine whether cidofovir (HPMPC) therapy administered by intravenous infusion can\n      extend the time to progression of peripheral cytomegalovirus (CMV) retinitis in AIDS\n      patients. To evaluate the safety and tolerance of HPMPC therapy when administered by\n      intravenous infusion in AIDS patients with CMV retinitis that is not immediately\n      sight-threatening. To evaluate the virologic effects of intravenous HPMPC therapy on CMV\n      shedding in urine, blood, and/or semen. To evaluate the impact of HPMPC therapy on visual\n      acuity."
        }, 
        "brief_title": "The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS", 
        "condition": [
            "Cytomegalovirus Retinitis", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Retinitis", 
                "Cytomegalovirus Retinitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomized to one of two treatment arms. Group A receives HPMPC by IV infusion\n      weekly for 2 consecutive weeks (induction) and then every other week (maintenance) with oral\n      probenecid and IV hydration. Group B receives no treatment until the time of retinitis\n      progression (deferred treatment), at which time they receive the same regimen as Group A,\n      provided retinitis progression is not immediately sight-threatening."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Antiretroviral agents.\n\n          -  Oral trimethoprim/sulfamethoxazole.\n\n          -  Aerosolized pentamidine.\n\n          -  Dapsone.\n\n          -  Fluconazole.\n\n          -  Rifabutin.\n\n          -  Filgrastim (G-CSF).\n\n          -  p24 vaccine.\n\n        Patients must have:\n\n          -  Diagnosis of AIDS by CDC criteria.\n\n          -  Diagnosis of peripheral (not immediately sight-threatening) CMV retinitis.\n\n          -  Visual acuity in the affected eye of >= three lines on the ETDRS (Early Treatment\n             Diabetic Retinopathy Study) chart at 1 m distance.\n\n          -  Life expectancy of at least 3 months.\n\n          -  Consent of parent or guardian in patients less than 18 years of age.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Acyclovir.\n\n          -  Prior ganciclovir, foscarnet, or CMV hyperimmune immunoglobulin if given solely as\n             prophylaxis.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Media opacity that precludes visualization of the fundus of both eyes.\n\n          -  Retinal detachment.\n\n          -  Clinically significant cardiac disease, including symptoms of ischemia, congestive\n             heart failure, or arrhythmia.\n\n          -  Active medical problems considered sufficient to hinder study compliance.\n\n          -  Known clinically significant allergy to probenecid.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Acyclovir (may be reinstituted following development of herpetic lesions).\n\n          -  Ganciclovir.\n\n          -  Foscarnet.\n\n          -  Amphotericin B.\n\n          -  Diuretics.\n\n          -  Aminoglycoside antibiotics.\n\n          -  CMV hyperimmune immunoglobulin.\n\n          -  Intravenous pentamidine.\n\n          -  Other nephrotoxic agents.\n\n          -  Other investigational drugs with potential nephrotoxicity.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Prior ganciclovir, foscarnet, or CMV hyperimmune immunoglobulin as therapy for CMV\n             disease (although permitted if previously received solely as prophylaxis).\n\n        Excluded within 1 week prior to study entry:\n\n          -  Amphotericin B.\n\n          -  Vidarabine.\n\n          -  Other nephrotoxic agents.\n\n          -  Aminoglycoside antibiotics.\n\n          -  Intravenous pentamidine. Drug or alcohol abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "48", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002437", 
            "org_study_id": "216A", 
            "secondary_id": "GS-93-106"
        }, 
        "intervention": [
            {
                "intervention_name": "Cidofovir", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Probenecid", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Probenecid", 
                "Cidofovir"
            ]
        }, 
        "keyword": [
            "Retinitis", 
            "Probenecid", 
            "Drug Therapy, Combination", 
            "Cytomegalovirus Infections", 
            "Acquired Immunodeficiency Syndrome", 
            "Antiviral Agents", 
            "cidofovir"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "Los Angeles County - USC Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92668"
                    }, 
                    "name": "UCI Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "Mount Zion Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Beth Israel Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Princeton", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "085406681"
                    }, 
                    "name": "Besselaar Associates"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14607"
                    }, 
                    "name": "Univ of Rochester Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "Univ of North Carolina Hosps"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78284"
                    }, 
                    "name": "Audie L Murphy Veterans Administration Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London SW 10", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Charing Cross and Westminster Med School"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "United Kingdom"
            ]
        }, 
        "official_title": "A Phase II/III Study of the Safety and Efficacy of 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) for the Treatment of Peripheral Cytomegalovirus Retinitis in Patients With AIDS", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "reference": {
            "citation": "Lalezari J, et al. A phase II/III randomized study of immediate versus deferred intravenous (IV) cidofovir (CDV, HPMPC) for the treatment of peripheral CMV retinitis (CMV-R) in patients with AIDS. Natl Conf Hum Retroviruses Relat Infect (2nd). 1995 Jan 29-Feb 2:170"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002437"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 1994"
    }, 
    "geocoordinates": {
        "Audie L Murphy Veterans Administration Hosp": "29.424 -98.494", 
        "Besselaar Associates": "40.366 -74.679", 
        "Beth Israel Hosp": "42.358 -71.06", 
        "Charing Cross and Westminster Med School": "51.498 -0.117", 
        "Los Angeles County - USC Med Ctr": "34.052 -118.244", 
        "Mount Zion Med Ctr": "37.775 -122.419", 
        "UCI Med Ctr": "33.788 -117.853", 
        "Univ of North Carolina Hosps": "35.913 -79.056", 
        "Univ of Rochester Med Ctr": "43.161 -77.611"
    }
}